ALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK plus NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA

被引：20
|
作者：
Gettinger, S. [1 ]
Bazhenova, L. [2 ]
Salgia, R. [3 ]
Langer, C. [4 ]
Gold, K. [5 ]
Rosell, R. [6 ]
Shaw, A. [7 ]
Weiss, G. J. [8 ]
Narasimhan, N. I. [9 ]
Dorer, D. J. [10 ]
Rivera, V. M. [11 ]
Clackson, T. [12 ]
Haluska, F. G. [13 ]
Camidge, R. [14 ]
机构：
[1] Yale Univ, Sch Med, Thorac Oncol Program, New Haven, CT USA
[2] UCSD Moores Canc Ctr, La Jolla, CA USA
[3] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] USP Dexeus Univ Inst, Inst Oncol Dr Rosell, Med Oncol Serv, Barcelona, Spain
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
[8] Scottsdale Healthcare, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[9] ARIAD Pharmaceut Inc, DMPK, Cambridge, MA USA
[10] ARIAD Pharmaceut Inc, Biostat, Cambridge, MA USA
[11] ARIAD Pharmaceut, Preclin & Translat Res, Cambridge, MA USA
[12] ARIAD Pharmaceut Inc, Res & Dev, Cambridge, MA USA
[13] ARIAD Pharmaceut Inc, Clin Res & Dev, Cambridge, MA USA
[14] Univ Colorado, Div Med Oncol, Denver, CO 80202 USA
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu349.71
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1292P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)
    Solomon, B. J.
    Ahn, J. S.
    Dziadziuszko, R.
    Barlesi, F.
    Nishio, M.
    Lee, D. H.
    Lee, J. S.
    Zhong, W. Z.
    Horinouchi, H.
    Mao, W.
    Hochmair, M. J.
    De Marinis, F.
    Migliorino, M. R.
    Bondarenko, I.
    Lohmann, T. O.
    Xu, T.
    Gavaldon, A. Cardona
    Bordogna, W.
    Ruf, T.
    Wu, Y. L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1295 - S1296
  • [32] Background of patients (pts) with ALK rearranged (ALK plus ) non-small-cell lung cancer (NSCLC), and efficacy and safety of ALK inhibitors (ALK-Is) in actual clinical practice: Multicenter retrospective study
    Ito, K.
    Saiki, H.
    Sakaguchi, T.
    Hayashi, K.
    Nishii, Y.
    Watanabe, F.
    Hataji, O.
    Okano, T.
    Naito, M.
    Ibata, H.
    Fujiwara, A.
    Yoshida, M.
    Itani, H.
    Tanigawa, M.
    Kobayashi, H.
    ANNALS OF ONCOLOGY, 2015, 26 : 140 - 140
  • [33] Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK plus NSCLC and intracranial metastases in a Phase 1/2 Study
    Camidge, D. R.
    Bazhenova, L. A.
    Salgia, R.
    Langer, C. J.
    Gold, K.
    Rosell, R.
    Shaw, A. T.
    Weiss, G. J.
    Dorer, D. J.
    Rivera, V. M.
    Conlan, M. G.
    Kerstein, D.
    Gettinger, S. N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S616 - S616
  • [34] Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC)
    Bang, Y.
    Kwak, E. L.
    Shaw, A. T.
    Camidge, D. R.
    Iafrate, A. J.
    Maki, R. G.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Clark, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [35] Impact of the EML4-ALK fusion variant on the efficacy of lorlatinib in patients (pts) with ALK-positive advanced non-small cell lung cancer (NSCLC)
    Bauer, Todd M.
    Martini, Jean-Francois
    Besse, Benjamin
    Lin, Chia-Chi
    Soo, Ross A.
    Riely, Gregory J.
    Ou, Sai-Hong Ignatius
    Toffalorio, Francesca
    Abbattista, Antonello
    Thurm, Holger
    Camidge, D. Ross
    Kao, Steven
    Chiari, Rita
    Gadgeel, Shirish
    Felip, Enriqueta
    Shaw, Alice T.
    Solomon, Benjamin J.
    CANCER RESEARCH, 2020, 80 (16)
  • [36] Lorlatinib for advanced ALK plus non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort
    Baldacci, S.
    Besse, B.
    Avrillon, V.
    Mennecier, B.
    Dubray-Longeras, P.
    Mazieres, J.
    Descourt, R.
    Duruisseaux, M.
    Quantin, X.
    Doubre, H.
    Monnet, I.
    Moro-Sibilot, D.
    Schneider, S.
    Cousin, S.
    Merle, P.
    Otto, J.
    Langlais, A.
    Morin, F.
    Westeel, V.
    Girard, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S843 - S843
  • [37] Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
    Gao, Guanghui
    Ni, Jian
    Wang, Yina
    Ren, Shengxiang
    Liu, Zhihua
    Chen, Gongyan
    Gu, Kangsheng
    Zang, Aimin
    Zhao, Jun
    Guo, Renhua
    He, Jianxing
    Lin, Xiaoyan
    Pan, Yueyin
    Ma, Zhiyong
    Wang, Zhehai
    Fan, Min
    Liu, Yunpeng
    Cang, Shundong
    Yang, Xinfeng
    Li, Weixia
    Wang, Quanren
    Zhou, Caicun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (06) : 964 - +
  • [38] Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK plus non-small cell lung cancer (NSCLC)
    Reckamp, Karen L.
    Infante, Jeffrey R.
    Blumenschein, George R.
    Wakelee, Heather
    Carter, Corey A.
    Gockerman, Jon P.
    Lovly, Christine
    Dukart, Gary
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James J.
    Horn, Leora
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S36 - S37
  • [39] Characteristics and outcomes of ALK plus non-small cell lung cancer patients in Korea
    Lim, Sung Hee
    Yoh, Kyung Ah
    Lee, Jong Seok
    Ahn, Myung-ju
    Kim, Yu Jung
    Kim, Se Hyun
    Zhang, Jie
    Patel, Dony
    Swallow, Elyse
    Kageleiry, Andrew
    Galebach, Philip
    Lee, Dongyeol
    Stein, Karen
    Degun, Ravi
    Park, Keunchil
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E239 - E245
  • [40] Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK plus non-small cell lung cancer (NSCLC)
    Lovly, Christine M.
    Infante, Jeffrey R.
    Blumenschein, George R.
    Reckamp, Karen
    Wakelee, Heather
    Carter, Corey A.
    VVagar, Saiama N.
    Neal, Joel
    Gockerman, Jon P.
    Dukart, Gary
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James J.
    Horn, Leora
    CANCER RESEARCH, 2016, 76
12345